Table 4.
p-value of miRNA concentration in mild HIE verses healthy control, moderate to severe HIE verses healthy control and mild HIE verses moderate-severe HIE respectively.
| miRNA |
Concentration of miRNA in mild HIE compared to control |
Concentration of mRNA in moderate-severe HIE compared to control |
Significance of miRNA |
|
|---|---|---|---|---|
| 1 | hsa.let.7b.5p | ↑ | ↑ | Suppress apoptosis and autophagy of mesenchymal stem cells (27)-Human |
| 2 | hsa.let.7d.5p | ↑ | ↑ | Involved in cell proliferation, invasion, angiogenesis and tumor metastatasis (28)-Human |
| 3 | hsa.let.7f.5p | ↑ | ↑ | Restores ischemia induced neovascularization (29)-Mouse |
| 4 | hsa.let.7g.5p | ↑ | ↑ | Inhibits cell migration and cell growth in hepatocellular carcinoma (30)-Human |
| 5 | hsa.let.7i.5p | ↑ | ↑ | Attenuates human brain microvascular damage (31)-Human |
| 6 | ath. mir167d | ↑ | ↑ | Studies in plants |
| 7 | hsa.mir.103a.3p | ↑ | ↑ | Contributes to angiotensin II induced renal inflammation (32)-Human |
| 8 | hsa.mir.107 | ↑ | ↑ | Regulate CDK5R1 expression in post mitotic neurons (33)-Human |
| 9 | hsa.mir.124.3p | ≈ | ↓ | Reduces caveolar density in porcine kidney (34)-Pig |
| 10 | hsa.mir.125b.5p | ≈ | ↑ | Regulates IL-1b induced inflammatory gene (35)-Human |
| 11 | hsa.mir.128.3p | ↑ | ↑ | Elevated in salmonella infection-decrease macrophage recruitment (36)-Human |
| 12 | hsa.mir.1285.5p | ↓ | ≈ | Unknown |
| 13 | hsa.mir.132.3p | ↑ | ↑ | Involved in endothelial tube formation and reduce myofibroblast differentiation (37)- Mouse |
| 14 | hsa.mir.134.5p | ↑ | ↑ | Mediates gene silencing (38)-Human |
| 15 | hsa.mir.142.3p | ↑ | ↑ | Negative regulation of IL-1 alpha production (39)-Human |
| 16 | hsa.mir.145.5p | ↑ | ↑ | Positive regulation of cellular response to hypoxia (40)-Human |
| 17 | hsa.mir.146a.5p | ↑ | ↑ | Negative regulation of IL-6 production (41)-Human |
| 18 | hsa.mir.150.5p | ↑ | ↑ | Regulation of vascular endothelial cell proliferation (42)-Human |
| 19 | hsa.mir.151a.3p | ↑ | ↑ | Promotes proliferation, epithelial-to-mesenchymal transition (43)-Human |
| 20 | hsa.mir.155.5p | ↑ | ↑ | Prevents necrotic cell death in cardiomyocyte progenitor (44)-Human |
| 21 | hsa.mir.15a.5p | ↑ | ↑ | Impair human circulating proangiogenic cell functions (45)-Human |
| 22 | hsa.mir.15b.3p | ↑ | ↑ | Enhances tumorigenesis and malignant transformation (46)-Human |
| 23 | hsa.mir.15b.5p | ↑ | ↑ | Targets amyloid precursor protein- Alzheimer's disease (47)-Human |
| 24 | hsa.mir.16.2.3p | ↑ | ↑ | Suppresses RAR-β (2) expression, increases tumor cell proliferation (48)-Human |
| 25 | hsa.mir.16.5p | ↑ | ↑ | regulate p53 signaling pathway (49)-Human |
| 26 | hsa.mir.17.5p | ↑ | ↑ | Suppresses toll-like receptor signaling in human leukemia cells (50)-Human |
| 27 | hsa.mir.181b.5p | ↑ | ↑ | Regulates ALX/FPR2 receptor expression in macrophages (51)-Human |
| 28 | cel.mir.70.3p | ↓ | ↓ | Unknown |
| 29 | hsa.mir.191.5p | ↑ | ↑ | Regulators of brain-derived neurotrophic factor (52)-Human |
| 30 | hsa.mir.195.5p | ↓ | ↑ | Impairs insulin signaling and glycogen metabolism (53)-Human |
| 31 | hsa.mir.197.3p | ↑ | ↑ | Negative regulation of interleukin-18 production (54)-Human |
| 32 | hsa.mir.206 | ↑ | ↑ | Silences the expression of Connexin 43(55)-Human |
| 33 | hsa.mir.20a.5p | ↑ | ↑ | Suppresses IL-17 production (56)-Human |
| 34 | hsa.mir.210.3p | ↑ | ↑ | Upregulates neuronal pentraxin 1 post hypoxic event (57)-Human |
| 35 | hsa.mir.214.3p | ↑ | ↑ | Suppresses XBP1-Mediated Endothelial Cells ANGIOGENESIS (58)-Human |
| 36 | hsa.mir.21.5p | ↑ | ↑ | Angiogenesis in Diabetic Retinopathy via PPARα (59)-Human |
| 37 | hsa.mir.22.3p | ↑ | ↑ | Induces endothelial progenitor cell senescence (60)-Human |
| 38 | hsa.mir.23a.3p | ↑ | ↑ | Apoptosis of cerebral vascular endothelial cells by down-regulating ZO-1 (61)-Human |
| 39 | hsa.mir.24.3p | ↑ | ↑ | Negative regulation of interferon-gamma production (62)-Human |
| 40 | hsa.mir.26b.5p | ↑ | ↑ | Negative regulation of chemokine production (63)-Human |
| 41 | hsa.mir.29b.3p | ↑ | ↑ | Negative regulation of cytokine-mediated signaling pathway (64)-Human |
| 42 | hsa.mir.301a.3p | ↑ | ↑ | Regulation of vascular associated smooth muscle cell proliferation (65)-Human |
| 43 | hsa.mir.30e.5p | ↑ | ↑ | Negative regulation of cardiac muscle cell apoptotic process (66)-Human |
| 44 | hsa.mir.323a.3p | ↑ | ↑ | Negative regulation of amyloid precursor protein (67)-Human |
| 45 | hsa.mir.328.3p | ↑ | ↑ | Contributes to adverse electrical remodeling in atrial fibrillation (68)-Human |
| 46 | hsa.mir.331.5p | ↓ | ↓ | Regulates Cell Proliferation and Glucose Metabolism (69)-Human |
| 47 | hsa.mir.338.3p | ↑ | ↑ | Negative regulation of cell migration (70)-Human |
| 48 | hsa.mir.342.3p | ↑ | ↑ | Unknown |
| 49 | hsa.mir.346 | ↓ | ↓ | Regulation of amyloid precursor protein (71)-Human |
| 50 | hsa.mir.34a.5p | ↑ | ↑ | Regulating steatosis by targeting PPARα expression (72)-Human |
| 51 | hsa.mir.34b.3p | ↓ | ↓ | Regulation of transporter activity (73)-Human |
| 52 | hsa.mir.34c.5p | ↓ | ≈ | Epithelial-mesenchymal transition in endometriosis (74)-Human |
| 53 | hsa.mir.370.3p | ↑ | ↓ | Suppresses the expression and induction of CYP2D6 (75)-Human |
| 54 | hsa.mir.382.5p | ↑ | ↑ | Unknown |
| 55 | hsa.mir.451a | ↑ | ↓ | Negative regulation of transporter activity (76)-Human |
| 56 | hsa.mir.483.3p | ≈ | ↑ | Simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells (77)-Human |
| 57 | hsa.mir.486.5p | ↓ | ↑ | Suppresses Cell Growth With the Involvement of a Target PIK3R1 (78)-Human |
| 58 | hsa.mir.491.5p | ↓ | ↓ | Inhibit cellular invasion in U251 and U87 glioma cells (79)-Human |
| 59 | hsa.mir.497.5p | ↑ | ↑ | Targets the TNF-α/NF-κB pathway (80)-Human |
| 60 | hsa.mir.5010.3p | ↓ | ↓ | Unknown |
| 61 | hsa.mir.532.5p | ↑ | ↑ | Unknown |
| 62 | hsa.mir.545.3p | ≈ | ≈ | Unknown |
| 63 | hsa.mir.7.5p | ↑ | ↑ | Negative regulation of amyloid-beta clearance (81)-Human |
| 64 | hsa.mir.7417.5p | ≈ | ↑ | Unknown |
| 65 | hsa.mir.885.5p | ≈ | ↑ | Suppressing the expression of lipid receptor and sterol transporter (82)-Human |
| 66 | hsa.mir.92a.1.5p | ↓ | ↓ | Decreases angiogenesis (83)-Human |
| 67 | hsa.mir.93.5p | ↑ | ↑ | Negative regulation of cell population proliferation (84)-Human |
| 68 | hsa.mir.98.5p | ≈ | ↑ | Modulates Cytokine Production in Systemic Lupus Erythematosus by Targeting IL-6 (85)-Human |